LifeVantage Corporation has completed its randomized, 12-week human clinical trial evaluating the efficacy of its innovative GLP-1 system for weight management. The study was conducted to explore the system’s potential to activate GLP-1 in users and support their health goals. The clinical trial, which began in mid-June 2024, involved 60 participants and was designed to assess the impact the innovative two-product system has on weight management, food cravings, and overall well-being, among other factors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFVN: